Welcome to our dedicated page for Hims & Hers Health SEC filings (Ticker: HIMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Hims & Hers Health, Inc. (NYSE: HIMS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, giving investors a detailed view of how this health and wellness platform operates and evolves. Through its filings with the U.S. Securities and Exchange Commission, Hims & Hers reports on financial performance, material events, governance changes, and key agreements that shape its digital health business.
Core documents such as annual reports on Form 10‑K and quarterly reports on Form 10‑Q (when available) explain the company’s subscription-based online revenue model, wholesale revenue from non-prescription product sales, and metrics like subscribers and monthly online revenue per average subscriber. These filings also discuss risks, accounting policies, and segment information that help readers understand the structure of the Hims & Hers platform and its growth drivers.
Current reports on Form 8‑K are particularly important for tracking significant developments. Recent 8‑Ks describe the authorization of a $250 million share repurchase program, the completion and use of a prior $100 million repurchase program, leadership changes such as the transition of the Chief Operating Officer role, and the entry into a long-term lease for a large facility in New Albany, Ohio, to support office, research and development, laboratory, manufacturing, and pharmaceutical dispensing activities. Other 8‑Ks furnish earnings press releases and shareholder letters, which outline quarterly financial results and management’s commentary.
Investors can also use SEC filings to follow strategic moves like the definitive agreement to acquire YourBio Health, which brings patented, virtually painless TAP and HALO blood sampling technologies into the Hims & Hers ecosystem, and to see how the company communicates material information through its designated disclosure channels. On Stock Titan, AI-powered tools can help summarize lengthy filings, highlight key sections related to revenue, capital allocation, share repurchases, and major contracts, and surface insider and governance-related information reported in applicable forms. This makes it easier to interpret complex regulatory documents and to connect them with the company’s broader strategy in digital health and wellness.
Hims & Hers Health (HIMS) CEO and 10% owner Andrew Dudum reported multiple insider transactions on 10/16/2025 under a Rule 10b5-1 plan adopted on August 28, 2024. He exercised stock options at an exercise price of $2.43 and sold shares in several tranches at weighted average prices disclosed within ranges, including $62.50–$62.87, $62.215–$63.13, and $63.31–$63.59.
Reported option exercises included 108,334 and 17,001 shares, followed by sales such as 39,531, 39,332, 39,111, 17,001, and smaller lots. After the transactions, reported direct holdings included 109,190 shares, with additional indirect holdings across multiple family trusts, each listed with its own balance.
Hims & Hers Health, Inc. (HIMS) filed a Form 144 notice for a proposed sale of up to 175,661 Class A shares through Fidelity Brokerage Services, with an aggregate market value of $11,029,998.25. The filing lists the NYSE as the exchange and an approximate sale date of 10/16/2025. Shares outstanding were 217,641,958.
The shares to be sold were acquired via an option grant (125,335 shares) exercised for cash on 10/16/2025 and restricted stock vestings on 06/15/2024 (2,792 shares), 09/15/2023 (4,182 shares), and 06/15/2023 (43,352 shares).
Recent sales over the past three months include examples such as 125,335 Class A shares on 07/21/2025 for $6,208,636.66 and 128,127 Class A shares on 09/16/2025 for $6,852,297.12.
Hims & Hers Health (HIMS) reported a Form 4 for Chief Commercial Officer Michael Chi. On 10/10/2025, he exercised 900 stock options at $6.82 and sold 900 Class A shares at $58.25, executed under a Rule 10b5-1 trading plan adopted on March 4, 2025. Following these transactions, he held 291,439 Class A shares directly and 115,362 derivative securities. The options vest over four years, with 1/48th vesting on September 10, 2022 and monthly thereafter.
Hims & Hers Health (HIMS) disclosed an insider transaction by its Chief Legal Officer. On 10/13/2025, the officer sold 2,637 shares of Class A common stock at $54.38 per share (Transaction Code S) and held 161,130 shares directly after the sale. The sales were effected under a Rule 10b5-1 trading plan adopted on August 28, 2024.
Hims & Hers Health, Inc. notice reports a proposed sale of 900 Class A shares through Fidelity Brokerage Services LLC on 10/10/2025 with an aggregate market value of $52,425. The filer indicates the shares derive from an option granted on 08/10/2022 and show cash payment on the stated sale date. The filing lists recent insider sales by Michael Y. Chi totaling $4,240,268.50 across eight transactions between 07/23/2025 and 10/01/2025.
The notice includes the required representation that the seller does not possess undisclosed material adverse information and identifies this as a Rule 144 notice of proposed sale. No earnings, guidance, or other operational metrics are disclosed in this form.
Insider transactions on 10/03/2025: the Chief Financial Officer, Oluyemi Okupe, adopted a Rule 10b5-1 plan and executed option exercises and open-market sales. The reporting shows 11,595 shares sold at an average weighted price of $57.7173 (range $57.41–$58.09), and two option exercises: 7,787 options at an exercise price of $5.01 and 3,808 options at $11.53. Post-transaction holdings include reported direct ownership entries for Class A common stock and optioned shares underlying 182,165 and 59,976 share tallies respectively as disclosed. The Form states vesting schedules for the options and notes sales were made under the 10b5-1 plan.
Michael Chi, Chief Commercial Officer of Hims & Hers Health, Inc. (HIMS), reported option exercise and an immediate sale under a pre-existing trading plan. On 10/01/2025 he exercised 250 stock options at an exercise price of $11.53 per share and sold 250 shares at $56.00 per share. After these transactions his reported beneficial ownership of Class A common stock was 291,439 shares and he holds 47,106 stock options outstanding. The Form 4 states the trades were made pursuant to a Rule 10b5-1 trading plan adopted on March 4, 2025, and that the options vest monthly over a four-year service period beginning April 1, 2023.
Hims & Hers Health, Inc. reported that on September 28, 2025 its Chief Operating Officer, Nader Kabbani, will move to an advisory role effective November 2, 2025 and will provide strategic guidance through July 2026. The company will promote Mike Chi, currently Chief Commercial Officer, to Chief Operating Officer effective on the Transition Date and will eliminate the separate Chief Commercial Officer role, consolidating operations, marketing, product, and commercial functions under Mr. Chi. Mr. Chi joined the company in April 2021 and has over 20 years of consumer internet experience. Compensation review by the Compensation Committee is planned; any changes require final approval.
Form 144/A from Hims & Hers Health, Inc. (HIMS) reports a proposed sale of 154,958 common shares through Goldman Sachs & Co. LLC on 09/22/2025, with an aggregate market value of $9,161,116.96. The filing shows 217,641,958 shares outstanding. The securities to be sold were acquired mainly as compensation: multiple Restricted Stock Unit grants on 09/15/2025, 09/15/2024, 06/15/2024 and cashless exercises of stock options on 02/24/2022 and 03/01/2023. The filing also discloses sales by Oluyemi Okupe during the past three months totaling several transactions, including a 145,000-share sale on 09/15/2025 for $8,026,083.50. The notice includes the seller's representation that no undisclosed material adverse information is known.
Hims & Hers Health, Inc. Form 144 notice shows a proposed sale of 250 Class A shares through Fidelity Brokerage Services (NYSE) on 10/01/2025, with an aggregate market value of $14,000. The shares are reported as acquired on 10/01/2025 via options granted 03/01/2023 and will be paid in cash.
The filing also lists seven prior Class A sales by Michael Y. Chi during July–September 2025 totaling $3,717,768.50 in gross proceeds. The filer affirms no undisclosed material adverse information and provides broker and sale dates but omits filer CIK and full contact details in the provided text.